Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPL | P40238 | 18/20 | 0.70 |
| ▸ | CTRC | Q99895 | 2/20 | 0.61 |
| ▸ | NSD2 | O96028 | 1/20 | 0.58 |
| ▸ | MMP14 | P50281 | 1/20 | 0.58 |
| ▸ | CASP6 | P55212 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL339726 | 0.85 | MPL (0.67) | MPLCTRCNSD2MMP14CASP6 | |
| SCHEMBL263650 | 0.82 | MPL (1.00) | MPLCTRCNSD2MMP14CASP6 | |
| SCHEMBL9271524 | 0.82 | MPL (1.00) | MPLCTRCNSD2MMP14CASP6 | |
| SCHEMBL31236789 | 0.82 | MPL (1.00) | MPLCTRCNSD2MMP14CASP6 | |
| SCHEMBL263651 | 0.82 | MPL (1.00) | MPLCTRCNSD2MMP14CASP6 | |
| SCHEMBL23169369 | 0.82 | SENP2 (0.57) | MPLCTRCMAPTKMT2ATDP1 | |
| SCHEMBL29436759 | 0.82 | MPL (1.00) | MPLCTRCNSD2MMP14CASP6 | |
| Ammonia Solution, Strong SCHEMBL18281619 | 0.81 | MPL (0.97) | MPLCTRCNSD2MMP14CASP6 | |
| Ammonia Solution, Strong SCHEMBL18281621 | 0.81 | MPL (0.97) | MPLCTRCNSD2MMP14CASP6 | |
| SCHEMBL18281628 | 0.81 | MPL (0.97) | MPLCTRCNSD2MMP14CASP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9084734-B2 | Peptide personal care compositions and methods for their use | DANISCO US INC. (US) | 2015-07-21 | — | — | US | disclosed |
| US-8962796-B2 | Modified variant Bowman Birk protease inhibitors | DANISCO US INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-20130195781-A1 | Modified Variant Bowman Birk Protease Inhibitors | DANISCO US INC. (US) | 2013-08-01 | — | — | US | disclosed |
| US-8394941-B2 | Modified variant Bowman Birk Protease Inhibitors | DANISCO US INC. (US) | 2013-03-12 | — | — | US | disclosed |
| US-8329200-B2 | Water in oil emulsion has moisturizer of glycerol, chitosan, Fucogel, propylene glycol, polyoxyethylene glycol, dipropylene glycol, butylene glycol, mannitol, lactic acid, glycine,, sodium 2-pyrrolidone-5-carboxylate, hyaluronic acid, urea, and/or salts; storage stability; acne, wrinkle resistance | BEIERSDORF AG (DE) | 2012-12-11 | — | — | US | disclosed |
| US-20120014885-A1 | Personal Care Compositions and Methods for Their Use | DANISCO US INC. | 2012-01-19 | — | — | US | disclosed |
| US-20110256608-A1 | Modified Variant Bowman Birk Protease Inhibitors | DANISCO US INC. (US) | 2011-10-20 | — | — | US | disclosed |
| EP-2344531-A1 | MODIFIED VARIANT BOWMAN BIRK PROTEASE INHIBITORS | Danisco US Inc. (US) | 2011-07-20 | — | — | EP | disclosed |
| US-7947475-B2 | Modified variant Bowman Birk protease inhibitors | DANISCO US INC. (US) | 2011-05-24 | — | — | US | disclosed |
| US-20100278882-A1 | USE OF PROTEIN MICROBEADS IN COSMETICS | BASF SE (DE) | 2010-11-04 | — | — | US | disclosed |
| US-20090098076-A1 | Method For the Production of a Keratin-Binding Effector Molecule | BASF SE (DE) | 2009-04-16 | — | — | US | disclosed |
| US-20080261844-A1 | Multicolor Cosmetics | BEIERSDORF AG (DE) | 2008-10-23 | — | — | US | disclosed |
| US-20080075684-A1 | Keratin-Binding Polypeptides | BASF AKTIENGESELLSCHAFT (DE) | 2008-03-27 | — | — | US | disclosed |
| EP-1880007-A2 | PERSONAL CARE COMPOSITIONS AND METHODS FOR THEIR USE | GENENCOR INTERNATIONAL, INC. (US) | 2008-01-23 | — | — | EP | disclosed |
| US-20070079754-A1 | Method of tanning human body by mysting or immersion at elevated temperature | MERCK PATENT GMBH (DE) | 2007-04-12 | — | — | US | disclosed |
| WO-2006121610-A2 | PERSONAL CARE COMPOSITIONS AND METHODS FOR THEIR USE | GENENCOR INTERNATIONAL, INC. (US) | 2006-11-16 | — | — | WO | disclosed |
| US-20060045856-A1 | Composition containing a dihydroxyacetone precursor | MERCK PATENT GMBH (DE) | 2006-03-02 | — | — | US | disclosed |
| US-20050276764-A1 | Topical use of bis-arylimidazo[1,2-a]thiolane derivatives | BEIERSDORF AG | 2005-12-15 | — | — | US | disclosed |
| US-20050074471-A1 | Self-foaming or foamy preparations comprising particulate hydrophobic and/or hydrophobized and/or oil-absorbent solid substances | BEIERSDORF AG (DE) | 2005-04-07 | — | — | US | disclosed |
| US-6620420-B2 | Cosmetic or dermatological application | BEIERSDORF AG (DE) | 2003-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050074471-A1 | Self-foaming or foamy preparations comprising particulate hydrophobic and/or hydrophobized and/or oil-absorbent solid substances | HBB, HBG1, FFAR1 | MPL 3786/4885CTRC 3356/4885NSD2 1498/4885 |
| US-20120014885-A1 | Personal Care Compositions and Methods for Their Use | CUTA, VEGFA, BDNF | MPL 2034/4885CTRC 1470/4885NSD2 4662/4885 |
| US-20130195781-A1 | Modified Variant Bowman Birk Protease Inhibitors | SERPINB1, BBC3, BRAP | MPL 2046/4885CTRC 628/4885NSD2 3840/4885 |
| US-20060045856-A1 | Composition containing a dihydroxyacetone precursor | TYR, CUTA, DERA | MPL 2680/4885CTRC 3276/4885NSD2 3564/4885 |
| US-20050276764-A1 | Topical use of bis-arylimidazo[1,2-a]thiolane derivatives | ITCH, TRPA1, TPH1 | MPL 3559/4885CTRC 1639/4885NSD2 2107/4885 |
| US-20070079754-A1 | Method of tanning human body by mysting or immersion at elevated temperature | TYR, CUTA, TREH | MPL 2942/4885CTRC 281/4885NSD2 1374/4885 |
| US-20080261844-A1 | Multicolor Cosmetics | CUTA, TYR, LBR | MPL 1467/4885CTRC 1846/4885NSD2 208/4885 |
| US-20090098076-A1 | Method For the Production of a Keratin-Binding Effector Molecule | KRT18, KRTCAP2, CUTA | MPL 4048/4885CTRC 2373/4885NSD2 4059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.